To include your compound in the COVID-19 Resource Center, submit it here.

Celyad gains on CAR T deal amendment

Celyad S.A. (Euronext:CYAD; NASDAQ:CYAD) amended a 2015 deal to increase its share of future revenues generated from chimeric antigen receptor (CAR) T assets partnered with Celdara Medical LLC (Lebanon, N.H.) and Dartmouth College (Hanover, N.H.).

Celyad gained €2.97 (11%) to €31.37

Read the full 412 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE